Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Head Of Eisai Sees MGI Buy As Road To Continued Growth

This article was originally published in PharmAsia News

Executive Summary

Eisai's president says the Japanese firm's purchase of MGI Pharma, a U.S. biotechnology company, was done to give Eisai a way to continue growing as patents for its moneymaking drugs expire over the next few years. Haruo Naito said MGI was attractive because of its pipeline of promising cancer drugs, with some of its candidates complementary with Eisai's own. He acknowledged Eisai depends heavily on its Alzheimer's drug Aricept (donepezil) and its heartburn and acid reflux medication Pariet/Aciphex (rabeprazole), with Aricept set to lose U.S. patent protection in 2010. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts